Angiogenesis stimulation in explanted hearts from patients pre-treated with intravenous prostaglandin E(1).

[1]  J. Isner,et al.  Therapeutic angiogenesis for heart failure , 1999, Nature Medicine.

[2]  Willem Flameng,et al.  Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188 , 1999, Nature Medicine.

[3]  G. Laufer,et al.  Bridging to heart transplantation: prostaglandin E1 versus prostacyclin versus dobutamine. , 1999, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[4]  A. Kitabatake,et al.  Beneficial effect of myocardial angiogenesis on cardiac remodeling process by amlodipine and MCI-154. , 1999, American journal of physiology. Heart and circulatory physiology.

[5]  G. FitzGerald,et al.  Phosphorylation of the Prostacyclin Receptor during Homologous Desensitization , 1998, The Journal of Biological Chemistry.

[6]  E. Ritz,et al.  Myocyte/capillary mismatch in the heart of uremic patients. , 1998, Journal of the American Society of Nephrology : JASN.

[7]  N. Voelkel,et al.  Prostaglandins induce vascular endothelial growth factor in a human monocytic cell line and rat lungs via cAMP. , 1997, American journal of respiratory cell and molecular biology.

[8]  S. Narumiya,et al.  Altered pain perception and inflammatory response in mice lacking prostacyclin receptor , 1997, Nature.

[9]  E. Hartter,et al.  Hemodynamic and neurohumoral effects of long-term prostaglandin E1 infusions in outpatients with severe congestive heart failure. , 1997, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[10]  H. Sinzinger,et al.  Effect of prostaglandin E1 infusion in severe chronic heart failure. , 1997, Prostaglandins.

[11]  G. Laufer,et al.  Prostaglandin E1--bridge to cardiac transplantation. Technique, dosage, results. , 1997, European heart journal.

[12]  K. Amann,et al.  Blockade of bradykinin B2 receptors prevents the increase in capillary density induced by chronic angiotensin-converting enzyme inhibitor treatment in stroke-prone spontaneously hypertensive rats. , 1997, Hypertension.

[13]  M. Daemen,et al.  Enhanced cellular proliferation in intact stenotic lesions derived from human arteriovenous fistulas and peripheral bypass grafts. Does it correlate with flow parameters? , 1996, Circulation.

[14]  L. Brown,et al.  VEGF, flk-1, and flt-1 expression in a rat myocardial infarction model of angiogenesis. , 1996, The American journal of physiology.

[15]  N. Weidner,et al.  Endothelial cell proliferation in prostatic carcinoma and prostatic hyperplasia: correlation with Gleason's score, microvessel density, and epithelial cell proliferation. , 1995, Laboratory investigation; a journal of technical methods and pathology.

[16]  J. Pearlman,et al.  Magnetic resonance mapping demonstrates benefits of VEGF–induced myocardial angiogenesis , 1995, Nature Medicine.

[17]  L. Crofford,et al.  Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin‐1: a potential mechanism for inflammatory angiogenesis , 1995, FEBS letters.

[18]  P. Gullino.  Prostaglandins and gangliosides of tumor microenvironment: their role in angiogenesis. , 1995, Acta oncologica.

[19]  Y. Kira,et al.  Rapid induction of vascular endothelial growth factor expression by transient ischemia in rat heart. , 1994, The American journal of physiology.

[20]  Atsushi Namiki,et al.  Indirect Angiogenic Cytokines Upregulate VEGF and bFGF Gene Expression in Vascular Smooth Muscle Cells, Whereas Hypoxia Upregulates VEGF Expression Only , 1994 .

[21]  S. Rodan,et al.  Induction of vascular endothelial growth factor expression by prostaglandin E2 and E1 in osteoblasts. , 1994, The Journal of clinical investigation.

[22]  C. Gajdusek,et al.  Basic fibroblast growth factor and transforming growth factor beta‐1: Synergistic mediators of angiogenesis in vitro , 1993, Journal of cellular physiology.

[23]  E. Spisni,et al.  Involvement of prostanoids in the regulation of angiogenesis by polypeptide growth factors. , 1992, Prostaglandins, leukotrienes, and essential fatty acids.

[24]  Y. Uchida,et al.  Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor. , 1992, Science.

[25]  P. Reddy,et al.  Utility of prostaglandin E1 in the pretransplantation evaluation of heart failure patients with significant pulmonary hypertension. , 1992, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[26]  J. S. Janicki,et al.  Reactive and reparative fibrillar collagen remodelling in the hypertrophied rat left ventricle: two experimental models of myocardial fibrosis. , 1990, Cardiovascular research.

[27]  C. Fletcher,et al.  QBEND/10, a new monoclonal antibody to endothelium: assessment of its diagnostic utility in paraffin sections , 1990, Histopathology.

[28]  W. Schaper,et al.  Molecular biologic concepts of coronary anastomoses. , 1990, Journal of the American College of Cardiology.

[29]  H. Sinzinger,et al.  Beneficial effect of long-term PGE1-treatment in left ventricular heart failure. , 1989, Prostaglandins, leukotrienes, and essential fatty acids.

[30]  L. Rubin,et al.  Prostacyclin and PGE1 treatment of pulmonary hypertension. , 1987, The American review of respiratory disease.

[31]  T. Mattfeldt,et al.  Dipyridamole-induced neoformation of capillaries in the rat heart. Quantitative stereological study on papillary muscles. , 1987, Laboratory investigation; a journal of technical methods and pathology.

[32]  R. Auerbach,et al.  PGE2 and Angiogenesis 1 , 1983, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[33]  P. Gullino,et al.  Role of prostaglandin E1 and copper in angiogenesis. , 1982, Journal of the National Cancer Institute.

[34]  B. Pitt,et al.  Hemodynamic effects of prostaglandin E1 infusion in patients with acute myocardial infarction and left ventricular failure. , 1982, American heart journal.

[35]  J. Vane,et al.  Intrarenal prostaglandin release attenuates the renal vasoconstrictor activity of angiotensin. , 1973, The Journal of pharmacology and experimental therapeutics.